Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Nov 20, 3:30PM CST

RARE : 46.91 (+1.10%)
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit GlobeNewswire - Sat Nov 9, 9:30AM CST

RARE : 46.91 (+1.10%)
Ultragenyx: Q3 Earnings Snapshot AP - Tue Nov 5, 3:11PM CST

Ultragenyx: Q3 Earnings Snapshot

RARE : 46.91 (+1.10%)
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update GlobeNewswire - Tue Nov 5, 3:01PM CST

RARE : 46.91 (+1.10%)
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update GlobeNewswire - Tue Oct 29, 3:05PM CDT

RARE : 46.91 (+1.10%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Oct 18, 3:30PM CDT

RARE : 46.91 (+1.10%)
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta GlobeNewswire - Mon Oct 7, 7:00AM CDT

RARE : 46.91 (+1.10%)
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
RARE's Wilson Disease Candidate Betters Standard Therapy in Study Zacks Investment Research - Fri Oct 4, 11:12AM CDT

Ultragenyx Pharmaceutical RARE reported positive updates from the Stage 1 cohorts of its phase I/II/III Cyprus2+ study evaluating UX701, an investigational AAV9 gene therapy, to treat Wilson disease. Stage...

KRYS : 182.28 (+2.35%)
RARE : 46.91 (+1.10%)
FULC : 3.05 (+2.01%)
ANIP : 55.87 (+1.40%)
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease GlobeNewswire - Thu Oct 3, 3:30PM CDT

RARE : 46.91 (+1.10%)
Ultragenyx: Q2 Earnings Snapshot AP - Thu Aug 1, 3:17PM CDT

Ultragenyx: Q2 Earnings Snapshot

RARE : 46.91 (+1.10%)

Barchart Exclusives

1 EV Stock Under $10 With 25% Upside Potential Barchart - 1 hour ago
This charging stock has been under heavy pressure lately amid concerns over the fate of EV tax credits. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot